Display options
Cite
Hüls A, Costa ACS, Dierssen M, et al. Medical vulnerability of individuals with Down syndrome to severe COVID-19-data from the Trisomy 21 Research Society and the UK ISARIC4C survey. EClinicalMedicine. 2021;33:100769doi: 10.1016/j.eclinm.2021.100769.
Hüls, A., Costa, A. C. S., Dierssen, M., Baksh, R. A., Bargagna, S., Baumer, N. T., Brandão, A. C., Carfi, A., Carmona-Iragui, M., Chicoine, B. A., Ghosh, S., Lakhanpaul, M., Manso, C., Mayer, M. A., Ortega, M. D. C., de Asua, D. R., Rebillat, A. S., Russell, L. A., Sgandurra, G., Valentini, D., Sherman, S. L., Strydom, A. (2021). Medical vulnerability of individuals with Down syndrome to severe COVID-19-data from the Trisomy 21 Research Society and the UK ISARIC4C survey. EClinicalMedicine, 33100769. https://doi.org/10.1016/j.eclinm.2021.100769
Hüls, Anke, et al. "Medical vulnerability of individuals with Down syndrome to severe COVID-19-data from the Trisomy 21 Research Society and the UK ISARIC4C survey." EClinicalMedicine vol. 33 (2021): 100769. doi: https://doi.org/10.1016/j.eclinm.2021.100769
Hüls A, Costa ACS, Dierssen M, Baksh RA, Bargagna S, Baumer NT, Brandão AC, Carfi A, Carmona-Iragui M, Chicoine BA, Ghosh S, Lakhanpaul M, Manso C, Mayer MA, Ortega MDC, de Asua DR, Rebillat AS, Russell LA, Sgandurra G, Valentini D, Sherman SL, Strydom A. Medical vulnerability of individuals with Down syndrome to severe COVID-19-data from the Trisomy 21 Research Society and the UK ISARIC4C survey. EClinicalMedicine. 2021 Mar;33:100769. doi: 10.1016/j.eclinm.2021.100769. Epub 2021 Feb 22. PMID: 33644721; PMCID: PMC7897934.
Copy Download .nbib Format: NLM
Share it on

EClinicalMedicine. 2021 Mar;33:100769. doi: 10.1016/j.eclinm.2021.100769. Epub 2021 Feb 22.

Medical vulnerability of individuals with Down syndrome to severe COVID-19-data from the Trisomy 21 Research Society and the UK ISARIC4C survey.

EClinicalMedicine

Anke Hüls, Alberto C S Costa, Mara Dierssen, R Asaad Baksh, Stefania Bargagna, Nicole T Baumer, Ana Claudia Brandão, Angelo Carfi, Maria Carmona-Iragui, Brian Allen Chicoine, Sujay Ghosh, Monica Lakhanpaul, Coral Manso, Miguel-Angel Mayer, Maria Del Carmen Ortega, Diego Real de Asua, Anne-Sophie Rebillat, Lauren Ashley Russell, Giuseppina Sgandurra, Diletta Valentini, Stephanie L Sherman, Andre Strydom,

Affiliations

  1. Department of Epidemiology and Gangarosa Department of Environmental Health, Rollins School of Public Health, Emory University, Atlanta, Georgia, USA.
  2. Departments of Pediatrics and of Psychiatry, School of Medicine, Case Western Reserve University, Cleveland, Ohio, USA.
  3. Centre for Genomic Regulation (CRG), The Barcelona Institute of Science and Technology, Barcelona, Spain.
  4. Universitat Pompeu Fabra (UPF), Barcelona, Spain.
  5. Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Spain.
  6. Institute of Psychiatry, Psychology, and Neuroscience, Department of Forensic and Neurodevelopmental Sciences, King's College London, London, United Kingdom.
  7. The London Down Syndrome (LonDownS) Consortium, London, United Kingdom.
  8. Fondazione Stella Maris IRCCS, Pisa, Italy.
  9. Boston Children's Hospital and Harvard Medical School, Boston, MA, USA.
  10. Hospital Israelita Albert Einstein, Sao Paulo, SP, Brazil.
  11. Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy.
  12. Sant Pau Memory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain.
  13. Barcelona Down Medical Center, Fundació Catalana de Síndrome de Down, Barcelona, Spain.
  14. Advocate Medical Group Adult Down Syndrome Center, Park Ridge, IL, USA.
  15. Cytogenetics and Genomics Reserach Unit. Department of Zoology, University of Calcutta.Kolkata. West Bengal, India.
  16. UCL- Great Ormond Street Institute of Child Health, London, United Kingdom.
  17. Whttington NHS Trust, London, United Kingdom; Down Syndrome Medical Interest Group, London, United Kingdom.
  18. CM: DOWN ESPAÑA, Madrid, Spain.
  19. Research Programme on Biomedical Informatics (GRIB), Hospital del Mar Medical Research Institute and DCEXS Universitat Pompeu Fabra, Barcelona, Spain.
  20. Department of Psychiatry, Research Institute i+12. Hospital Universitario 12 de Octubre. Madrid, Spain.
  21. Department of Internal Medicine and Instituto de Investigación Biomédica-La Princesa, Hospital Universitario de La Princesa, Madrid, Spain.
  22. Institut Jérôme Lejeune, Paris, France.
  23. Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, Georgia, USA.
  24. Department of Developmental Neuroscience, IRCCS Fondazione Stella Maris, Pisa, Italy.
  25. Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
  26. Pediatric Unit, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
  27. Department of Human Genetics, School of Medicine, Emory University, Atlanta, Georgia, USA.
  28. South London and the Maudsley NHS Foundation Trust.

PMID: 33644721 PMCID: PMC7897934 DOI: 10.1016/j.eclinm.2021.100769

Abstract

BACKGROUND: Health conditions, immune dysfunction, and premature aging associated with trisomy 21 (Down syndrome, DS) may impact the clinical course of COVID-19.

METHODS: The T21RS COVID-19 Initiative launched an international survey for clinicians or caregivers on patients with COVID-19 and DS. Data collected between April and October 2020 (N=1046) were analysed and compared with the UK ISARIC4C survey of hospitalized COVID-19 patients with and without DS.

FINDINGS: The mean age of COVID-19 patients with DS in the T21RS survey was 29 years (SD = 18). Similar to the general population, the most frequent signs and symptoms of COVID-19 were fever, cough, and shortness of breath. Joint/muscle pain and vomiting or nausea were less frequent (

INTERPRETATION: Leading signs/symptoms of COVID-19 and risk factors for severe disease course are similar to the general population. However, individuals with DS present significantly higher rates of medical complications and mortality, especially from age 40.

FUNDING: Down Syndrome Affiliates in Action, DSMIG-USA, GiGi's Playhouse, Jerome Lejeune Foundation, LuMind IDSC Foundation, The Matthew Foundation, NDSS, National Task Group on Intellectual Disabilities and Dementia Practices.

© 2021 The Author(s).

Conflict of interest statement

Dr. Chicoine reports other from Woodbine House Publishing, other from Various Grateful Families of Patients, outside the submitted work; Dr. Strydom reports grants from MRC, grants from EC - Horizon 2

References

  1. J Biomed Inform. 2009 Apr;42(2):377-81 - PubMed
  2. Diabetologia. 2006 Jun;49(6):1179-82 - PubMed
  3. Crit Care. 2020 May 26;24(1):263 - PubMed
  4. OTO Open. 2020 Sep 11;4(3):2473974X20957975 - PubMed
  5. Acta Neurol Belg. 2020 May 22;: - PubMed
  6. Nat Rev Dis Primers. 2020 Feb 6;6(1):9 - PubMed
  7. Clin Exp Immunol. 2011 Apr;164(1):9-16 - PubMed
  8. J Infect. 2020 Jun;80(6):607-613 - PubMed
  9. Front Behav Neurosci. 2015 Jul 30;9:194 - PubMed
  10. Hypertension. 2020 Mar;75(3):819-825 - PubMed
  11. JAMA Neurol. 2019 Feb 1;76(2):152-160 - PubMed
  12. Alzheimers Dement. 2015 Jun;11(6):700-9 - PubMed
  13. Pediatrics. 2007 Oct;120(4):e1076-81 - PubMed
  14. J Neurodev Disord. 2020 Jan 23;12(1):4 - PubMed
  15. JAMA. 2020 May 26;323(20):2052-2059 - PubMed
  16. Sci Rep. 2021 Jan 21;11(1):1930 - PubMed
  17. Pediatrics. 2020 Jun;145(6): - PubMed
  18. Intellect Dev Disabil. 2012 Apr;50(2):92-108 - PubMed
  19. Emerg Infect Dis. 2010 Aug;16(8):1312-4 - PubMed
  20. Int J Immunogenet. 2010 Aug;37(4):233-7 - PubMed
  21. N Engl J Med. 2020 May 21;382(21):2005-2011 - PubMed
  22. J Intellect Disabil Res. 2020 Jul;64(7):489-496 - PubMed
  23. Immun Ageing. 2011 Apr 16;8(1):4 - PubMed
  24. Ann Intern Med. 2020 Oct 21;: - PubMed
  25. J Clin Med. 2020 Jun 04;9(6): - PubMed
  26. Res Dev Disabil. 2016 Oct;57:181-92 - PubMed
  27. Disabil Health J. 2020 Jul;13(3):100942 - PubMed
  28. J Orofac Pain. 2003 Fall;17(4):347-53 - PubMed
  29. J Biomed Inform. 2019 Jul;95:103208 - PubMed
  30. MMWR Morb Mortal Wkly Rep. 2020 Jun 19;69(24):759-765 - PubMed
  31. Cell Rep Med. 2020 May 19;1(2):100019 - PubMed
  32. BMJ. 2020 May 22;369:m1985 - PubMed

Publication Types

Grant support